|
|
Exchange: |
Nasdaq Small Cap |
Security
Type: |
Common |
Shares
Out: |
52,373,000 |
Market
Cap: |
2.32(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$30.85 - $52.9 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Health Services |
Level
III Sector: |
Medical Laboratories & Research |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 474 |
Guru Rank Value : 3 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile Vericel is a biopharmaceutical company providing cell therapies for the sports medicine and severe burn care markets. Co.'s products include: MACI®, which is an autologous cellularized scaffold product indicated for the repair of symptomatic, full-thickness cartilage defects of the knee with or without bone involvement in adults; and Epicel®, which is a permanent skin replacement for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns comprising greater than or equal to 30% of total body surface area. Co. also holds a license for North American rights to NexoBrid®, a registration-stage biological orphan product for debridement of severe thermal burns.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
126,152 |
256,428 |
308,234 |
348,833 |
Total Sell Value |
$5,873,218 |
$11,298,513 |
$13,114,420 |
$14,216,679 |
Total People Sold |
4 |
7 |
7 |
7 |
Total Sell Transactions |
9 |
26 |
34 |
37 |
End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Colangelo Dominick |
President and CEO |
|
2024-03-13 |
4 |
AS |
$44.67 |
$781,725 |
D/D |
(17,500) |
194,870 |
|
-0% |
|
Colangelo Dominick |
President and CEO |
|
2024-03-13 |
4 |
OE |
$3.02 |
$52,850 |
D/D |
17,500 |
212,370 |
|
- |
|
Halpin Michael |
Chief Operating Officer |
|
2024-03-11 |
4 |
AS |
$44.71 |
$352,047 |
D/D |
(7,874) |
949 |
|
-0% |
|
Flynn Sean C. |
SVP, General Counsel |
|
2024-03-08 |
4/A |
AS |
$45.33 |
$367,853 |
D/D |
(8,115) |
167 |
|
- |
|
Flynn Sean C. |
SVP, General Counsel |
|
2024-03-08 |
4 |
S |
$45.33 |
$367,853 |
D/D |
(8,115) |
167 |
|
-1% |
|
Siegal Jonathan |
Principal Accounting Officer |
|
2024-03-07 |
4 |
S |
$45.00 |
$73,530 |
D/D |
(1,634) |
1,400 |
|
-2% |
|
Zerbe Robert L Md |
|
|
2024-02-20 |
4 |
AS |
$50.01 |
$36,107 |
D/D |
(722) |
23,395 |
|
-10% |
|
Zerbe Robert L Md |
|
|
2024-02-20 |
4 |
OE |
$3.74 |
$2,700 |
D/D |
722 |
24,117 |
|
- |
|
Flynn Sean C. |
SVP, General Counsel |
|
2024-02-20 |
4 |
D |
$49.50 |
$160,875 |
D/D |
(3,250) |
8,282 |
|
- |
|
Flynn Sean C. |
SVP, General Counsel |
|
2024-02-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,075 |
9,059 |
|
- |
|
Halpin Michael |
Chief Operating Officer |
|
2024-02-20 |
4 |
D |
$49.50 |
$283,685 |
D/D |
(5,731) |
8,823 |
|
- |
|
Halpin Michael |
Chief Operating Officer |
|
2024-02-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
11,887 |
10,155 |
|
- |
|
Mara Joseph Anthony Jr |
Chief Financial Officer |
|
2024-02-20 |
4 |
D |
$49.50 |
$112,266 |
D/D |
(2,268) |
19,288 |
|
- |
|
Mara Joseph Anthony Jr |
Chief Financial Officer |
|
2024-02-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,380 |
20,097 |
|
- |
|
Hopper Jonathan Mark |
Chief Medical Officer |
|
2024-02-20 |
4 |
D |
$49.50 |
$153,747 |
D/D |
(3,106) |
57,953 |
|
- |
|
Hopper Jonathan Mark |
Chief Medical Officer |
|
2024-02-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,075 |
58,695 |
|
- |
|
Colangelo Dominick |
President and CEO |
|
2024-02-20 |
4 |
D |
$49.50 |
$892,238 |
D/D |
(18,025) |
194,870 |
|
- |
|
Colangelo Dominick |
President and CEO |
|
2024-02-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
38,887 |
199,013 |
|
- |
|
Siegal Jonathan |
Principal Accounting Officer |
|
2024-02-20 |
4 |
D |
$49.50 |
$63,657 |
D/D |
(1,286) |
3,034 |
|
- |
|
Siegal Jonathan |
Principal Accounting Officer |
|
2024-02-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,920 |
3,203 |
|
- |
|
Colangelo Dominick |
President and CEO |
|
2024-02-15 |
4 |
AS |
$48.85 |
$854,875 |
D/D |
(17,500) |
174,008 |
|
-10% |
|
Colangelo Dominick |
President and CEO |
|
2024-02-15 |
4 |
OE |
$3.02 |
$52,850 |
D/D |
17,500 |
191,508 |
|
- |
|
Colangelo Dominick |
President and CEO |
|
2024-02-14 |
4 |
AS |
$46.99 |
$822,325 |
D/D |
(17,500) |
174,008 |
|
-7% |
|
Colangelo Dominick |
President and CEO |
|
2024-02-14 |
4 |
OE |
$3.02 |
$52,850 |
D/D |
17,500 |
191,508 |
|
- |
|
Colangelo Dominick |
President and CEO |
|
2024-02-12 |
4 |
D |
$47.42 |
$164,879 |
D/D |
(3,477) |
174,008 |
|
- |
|
402 Records found
|
|
Page 2 of 17 |
|
|